Once-Monthly MariTide Promising in Phase 2 Despite GI Issues ...Middle East

Patients with obesity, with or without diabetes, lose up to 20% body weight and show A1c reductions with the novel agent maridebart cafraglutide, though nearly all experience GI side effects. Medscape Medical News

Hence then, the article about once monthly maritide promising in phase 2 despite gi issues was published today ( Thursday 26/06/2025 - 12:03 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Once-Monthly MariTide Promising in Phase 2 Despite GI Issues )

Also on site :

• 12-year old Russian beats world chess champion
• Hundreds of popular grocery, drug-store items recalled due to ‘filth' at Midwest distribution center
• Body recovered from Lake Natoma amid search for missing man